New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2013
07:42 EDTGB, CERN, GWPH, AVNR, MASI, ABMD, ATHX, AGN, ONCY, SGMOPiper Jaffray to hold a conference
25th Annual Healthcare Conference is being held in New York on December 3-4 with webcasted company presentations to begin on December 4 at 8 am. Webcast Link
News For ABMD;SGMO;AGN;MASI;ONCY;ATHX;AVNR;GWPH;CERN;GB From The Last 14 Days
Check below for free stories on ABMD;SGMO;AGN;MASI;ONCY;ATHX;AVNR;GWPH;CERN;GB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
07:04 EDTAGNAllergan initiated with a Buy at Sterne Agee
Target $142.
April 15, 2014
10:00 EDTCERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:05 EDTABMDAbiomed acquires exclusive license for Opsens' optical sensor technology
Abiomed announced its acquisition of an exclusive license from collaboration partner Opsens. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab. This licensing agreement, which secures Abiomed's rights to the technology and gives Abiomed the right to manufacture the sensors, is a continuation of an initial collaboration, entered into between Opsens and Abiomed in 2010.
April 14, 2014
16:55 EDTCERNCerner reinstated with an Outperform at Raymond James
Subscribe for More Information
06:49 EDTONCYOncolytics Biotech reports evaluation of clinical study with REOLYSIN
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined REOLYSIN in panels of both normal and malignant liver cells and administered either REOLYSIN or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:47 EDTONCYOncolytics Biotech collaborators present preclinical research on liver cancer
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined Reolysin in panels of both normal and malignant liver cells and administered either Reolysin or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. The study results showed that reovirus infection of primary human liver cells and HCC lines induced a robust type I interferon response; that reovirus-conditioned media from both primary human liver cells and JHH1 cells potently inhibits HCV and HBV in vitro with these effects abrogated by the blockade of the type I interferon receptor and soluble interferon beta; and that reovirus inhibits HCC xenograft growth and HCV replication in vivo. The researchers concluded that the results described a novel dual anti-viral and anti-cancer mechanism for reovirus in HBV/HCV-positive HCC and that reovirus treatment of patients with HBV/HCV positive HCC will likely lead to the suppression, rather than exacerbation, of the underlying oncogenic viral infection. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Subscribe for More Information
April 11, 2014
18:44 EDTAGNJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
April 10, 2014
10:00 EDTGBOn The Fly: Analyst Initiation Summary
Apple (AAPL) initiated with a Buy at Deutsche Bank... Crocs (CROX) initiated with a Buy at Buckingham... Deckers Outdoor (DECK) initiated with a Buy at Buckingham... EMC (EMC) initiated with a Buy at Deutsche Bank... HP (HPQ) initiated with a Buy at Deutsche Bank... IBM (IBM) initiated with a Hold at Deutsche Bank... NeoPhotonics (NPTN) coverage resumed with a Market Perform at Raymond James... NetApp (NTAP) initiated with a Hold at Deutsche Bank... Nutrisystem (NTRI) initiated with a Buy at B. Riley... Questar (STR) initiated with an Underperform at BofA/Merrill... S&T Bancorp (STBA) initiated with an Outperform at Raymond James... STB Systems Inc (STBI) initiated with an Outperform at Raymond James... Skechers (SKX) initiated with an Underperform at Buckingham... Steven Madden (SHOO) initiated with a Buy at Buckingham... UGI Corporation (UGI) initiated with a Buy at BofA/Merrill... Web.com (WWWW) initiated with a Neutral at Buckingham... Ally Financial (ALLY) initiated with a Buy at BTIG... Visteon (VC) initiated with a Buy at Citigroup... Greatbatch (GB) initiated with a Buy at KeyBanc... Steris (STE) initiated with a Buy at KeyBanc... Cooper Companies (COO) initiated with a Hold at KeyBanc... Hill-Rom (HRC) initiated with a Hold at KeyBanc... Invacare (IVC) initiated with a Hold at KeyBanc... Teleflex (TFX) initiated with a Hold at KeyBanc... Provident Financial (PROV) initiated with a Market Perform at Keefe Bruyette... UMH Properties (UMH) initiated with a Hold at Wunderlich.
07:34 EDTABMDAbiomed shares attractive following recent weakness, says Stephens
Stephens believes Abiomed shares are attractively valued following their recent weakness given the stock's valuation relative to peers. The firm says Abiomed remains one of its top ideas and reiterates its Overweight rating and $34 price target on the stock.
07:31 EDTGBGreatbatch initiated with a Buy at KeyBanc
Subscribe for More Information
April 8, 2014
09:00 EDTGWPHGW Pharmaceuticals falls 2.3%
GW Pharmaceuticals is down 2.3%, or $1.18, to $50.16
09:00 EDTONCYOncolytics Biotech rises 12.4%
Subscribe for More Information
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.
06:38 EDTONCYOncolytics Biotech reports tumor stabilization or shrinkage in REOLYSIN study
Oncolytics Biotech announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-na´ve head and neck cancers, or REO 018. Highlights include: 118 patients had loco-regional head and neck disease, with or without distal metastases An intent-to-treat analysis of the overall survival, or OS, of the 118 patients with loco-regional disease was performed on all patients to the median PFS in each arm, censoring any patients who received post-discontinuation therapy at the date at which they commenced the first of these therapies. This analysis demonstrated a statistically significant improvement in OS for the test arm versus the control arm; and the 118 patients with loco-regional head and neck disease, with or without distal metastases, were evaluated for percentage magnitude of tumour shrinkage at the first post-treatment scan. The test arm showed a statistical trend towards better tumour stabilization or shrinkage over the control arm. There were 47 patients with distal metastases alone. At the time of the analysis, eight of the 47 patients were still alive. The test arm patients in this group maintained a PFS benefit over control arm patients for five cycles of therapy. There are too few patients to power a statistical analysis of the PFS and OS of this patient group; and the 47 patients with distal metastases alone were evaluated for percentage magnitude of tumour shrinkage at the first post-treatment scan (performed at approximately six weeks). The test arm demonstrated statistically significantly better tumour stabilization or shrinkage than the control arm.
06:37 EDTONCYOncolytics Biotech to host conference call
Conference call to discuss additional data analysis from the Company's REO 018 trial in head and neck cancers will be held on April 8 at 7:45 am. Webcast Link
06:35 EDTONCYOncolytics Biotech announces additional data from REO 018 study of Reolysin
Subscribe for More Information
April 7, 2014
08:31 EDTMASIMasimo PVI helps clinicians optimize fluid administration
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use